{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Sequential Interventions for Posttransplant Lymphoproliferative Disease in Adult Solid Organ Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to evaluate the efficacy of a sequential treatment algorithm"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adult solid organ transplant recipients with biopsy-proven PTLD. The trial was conducted across multiple centers."
      },
      "Intervention": {
        "score": 2,
        "evidence": "starting with reduction in immunosuppressives (RI), followed by interferon (IFN) alpha2b, and chemotherapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to evaluate the efficacy of a sequential treatment algorithm for posttransplant lymphoproliferative disease (PTLD) in adult solid organ transplant recipients"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "RI resulted in 1 partial response (12.5%) and no CR."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Sixteen eligible patients were analysed."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Sixteen eligible patients were analysed."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "RI resulted in 1 partial response (12.5%) and no CR. Progressive disease occurred in 50% and rejection in 38%. Only 1 patient achieved durable CR with IFN. Seven patients received chemotherapy, with 5 achieving CR, 4 of which were durable beyond 2 years."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not detailed."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}